RxDoctor Payments Data

Joy Tomko

Optometrist · Portsmouth, VANPI 1366771024

Payments from drug & device makers

$2,359in general payments, 2019–2025

Across 97 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$429
  • Bausch & Lomb Americas Inc.$367
  • Tarsus Pharmaceuticals, Inc.$295
  • AbbVie$174
  • Shire North American Group Inc$160
  • Novartis$134
  • plus $800 from 16 others

What the payments were for

  • Food & beverage$2,34299%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,359 in reported general payments places this provider in the 75th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$195,333
Medicare patients
1,164
Services billed
2,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast58$76,961
RestasisCyclosporine33$48,984
LumiganBimatoprost29$16,341
Cyclosporine11$9,144
RocklatanNetarsudil Mesylat/Latanoprost12$7,055
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$6,562
Brimonidine Tartrate71$6,090
CombiganBrimonidine Tartrate/Timolol11$5,973
SimbrinzaBrinzolamide/Brimonidine Tart20$4,690
Loteprednol Etabonate16$3,327
Travoprost24$3,131
Brinzolamide12$2,842
Timolol Maleate93$2,412
Latanoprost248$2,165
Prednisolone Acetate46$1,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$367$76,96158 claims
AbbVieRestasis, Lumigan, Combigan$174$71,29873 claims
Aerie Pharmaceuticals, Inc.Rocklatan$15$7,05512 claims
AlconSimbrinza$27$4,69020 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$126$3,32716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Portsmouth

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →